Journals / Turkish Journal of Medical Sciences / 2015 / Cilt: 45 - Sayı: 1

Clinicopathological importance of Ki-67, p27, and p53 expression in gastric cancer

Pages
118–128
Publication Date
2015-03-15
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In addition, immunopathological identification of p27 may be helpful to define patients with gastric cancer who are at an increased risk of death.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:To assess the prognostic value of Ki-67, p27, and p53 immunoreactivity in human gastric cancer.
📊
Key Findings & Data:Materials and methods: A total of 84 patients with gastric cancer participated in our study.
💡
Conclusion & Impact:In addition, immunopathological identification of p27 may be helpful to define patients with gastric cancer who are at an increased risk of death.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Gastric cancer · p27 · p53

Abstract

To assess the prognostic value of Ki-67, p27, and p53 immunoreactivity in human gastric cancer. Materials and methods: A total of 84 patients with gastric cancer participated in our study. We categorized tumors as intestinal and diffuse types, with reference to Lauren's classification. Ki-67, p27, and p53 immunoreactivity were correlated with patient's age, tumor type, grade, lymph node status, extent of invasion, tumor-node-metastasis (TNM) stage, and survival. Results: Decreased expression of p27 (50% positivity of cells) were determined in 41 (48.8%) and 29 (36.9%) tumor specimens, respectively, and were connected with both the TNM stage (P = 0.007 and P = 0.039, respectively), and the extent of tumor invasion (P = 0.025 and P = 0.004, respectively). Kaplan-Meier methods showed a remarkable effect of reduced p27 expression on survival time (P = 0.003). In contrast, we observed no notable relationship between survival time and p53 or Ki-67 immunoreactivity (P = 0.372 and P = 0.401, respectively). Conclusion: A decrease in p27 expression and overexpression of p53 or Ki-67 may cause advancing and metastatic illness in patients with gastric carcinoma. In addition, immunopathological identification of p27 may be helpful to define patients with gastric cancer who are at an increased risk of death.

Özet

To assess the prognostic value of Ki-67, p27, and p53 immunoreactivity in human gastric cancer. Materials and methods: A total of 84 patients with gastric cancer participated in our study. We categorized tumors as intestinal and diffuse types, with reference to Lauren's classification. Ki-67, p27, and p53 immunoreactivity were correlated with patient's age, tumor type, grade, lymph node status, extent of invasion, tumor-node-metastasis (TNM) stage, and survival. Results: Decreased expression of p27 (50% positivity of cells) were determined in 41 (48.8%) and 29 (36.9%) tumor specimens, respectively, and were connected with both the TNM stage (P = 0.007 and P = 0.039, respectively), and the extent of tumor invasion (P = 0.025 and P = 0.004, respectively). Kaplan-Meier methods showed a remarkable effect of reduced p27 expression on survival time (P = 0.003). In contrast, we observed no notable relationship between survival time and p53 or Ki-67 immunoreactivity (P = 0.372 and P = 0.401, respectively). Conclusion: A decrease in p27 expression and overexpression of p53 or Ki-67 may cause advancing and metastatic illness in patients with gastric carcinoma. In addition, immunopathological identification of p27 may be helpful to define patients with gastric cancer who are at an increased risk of death.

🔖

Cite This Article

ÇALIK, M., DEMİRCİ, E., ALTUN, E., ÇALIK, İ. (2015). Clinicopathological importance of Ki-67, p27, and p53 expression in gastric cancer. Turkish Journal of Medical Sciences, Cilt: 45 - Sayı: 1, 118–128. https://ajindex.com/articles/209656

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. André AR, Ferreira MVP, Mota RMS, Ferrasi AC, Pardini MI, Rabenhorst SH. Gastric adenocarcinoma and Helicobacter pylori: correlation with p53 mutation and p27 immunoexpression. Cancer Epidemiol 2010; 34: 618–625.
  2. Altınkaynak K, Bilici M, Bakan N, Akçay F. Circulating levels of IGF-I and IGFBP-3 in gastric cancer. Turk J Med Sci 2012; 42: 1458–1462. 5. Nagini S. Carcinoma of the stomach: a review of epidemiology, pathogenesis, molecular genetics and chemoprevention. World J Gastrointest Oncol 2012; 4: 156–169.
  3. Mills SA, Contos MJ, Goel R. The stomach. In: Silverberg SG, DeLellis RA, Frable WJ, LiVolsi VA, Wick MR, editors. Silverberg’s Principles and Practice of Surgical Pathology and Cytopathology. 4th ed. Philadelphia, PA, USA: Churchill Livingstone; 2006. pp. 1321–1372. Rosai J. Stomach. In: Rosai J, editor. Rosai and Ackerman’s Surgical Pathology. 9th ed. London, UK: Elsevier; 2004. pp. 649–711.
  4. Shibata A, Longacre TA, Puligandla B, Parsonnet J, Habel LA. Histological classification of gastric adenocarcinoma for epidemiological research: concordance between pathologists. Cancer Epidemiol Biomarkers Prev 2001; 10: 75–78. 9. Craanen ME, Blok P, Dekker W, Offerhaus GJ, Tytgat GN. Chronology of p53 protein accumulation in gastric carcinogenesis. Gut 1995; 36: 848–885.
  5. Correa P, Piazuelo MB, Camargo MC. Etiopathogenesis of gastric cancer. Scand J Surg 2006; 95: 218–224.
  6. Bashir SA, Pandith AA, Yousuf A, Parveen N, Siddiqi MA, Muddassar S, Andrabi KI, Abdin MZ. Lack of p16 gene mutations in gastric cancers in Kashmir. Asian Pac J Cancer Prev 2010; 11: 339–342.
  7. Lloyd RV, Erickson LA, Jin L, Kulig E, Qian X, Cheville JC, Scheithauer BW. p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol 1999; 154: 313–323.
  8. Sandhu C, Slingerland J. Deregulation of the cell cycle in cancer. Cancer Detect Prev 2000; 24: 107–118.
  9. Abbas NF, El-Sharkawy SL, Fadel MT, Abd El-Monem El- Shaer M, Abd El-Megid B, El-Said Abd El-Aal W. Combined expression of P27 and P53 in human gastric carcinoma. Report and Opinion 2010; 2: 27–34.
  10. Wen S, So Y, Singh K, Slingerland JM, Resnick MB, Zhang S, Ruiz V, Moss SF. Promotion of cytoplasmic mislocalization of p27 by Helicobacter pylori in gastric cancer. Oncogene 2012; 31: 1771–1780.
  11. Gamboa-Dominguez A, Seidl S, Reyes-Gutierrez E, Hermannstädter C, Quintanilla-Martinez L, Busch R, Höfler H, Fend F, Luber B. Prognostic significance of p21WAF1/CIP1, p27Kip1, p53 and E-cadherin express